[#item_full_content] [[{“value”:”Recently, President Donald Trump signed an executive order reclassifying cannabis as a Schedule 3 drug, easing access to banking services and enabling normal business expense deductions for operators in the sector.
This regulatory shift could be particularly important for Tilray Brands, which may be able to leverage its existing hemp operations to expand more rapidly into the U.S. market.
We will now examine how easier banking access and expense deductions in the U.S. could influence Tilray…”}]] Read More
Trump’s Cannabis Reclassification Might Change The Case For Investing In Tilray Brands (TLRY)
ByPot Shop News
January 4, 2026